William Lewis Sells 6,830 Shares of Insmed, Inc. (NASDAQ:INSM) Stock

Insmed, Inc. (NASDAQ:INSM - Get Free Report) CEO William Lewis sold 6,830 shares of the company's stock in a transaction dated Tuesday, July 15th. The shares were sold at an average price of $102.37, for a total transaction of $699,187.10. Following the completion of the sale, the chief executive officer owned 233,924 shares in the company, valued at approximately $23,946,799.88. This trade represents a 2.84% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

William Lewis also recently made the following trade(s):

• On Monday, June 16th, William Lewis sold 129,805 shares of Insmed stock. The shares were sold at an average price of $100.39, for a total value of $13,031,123.95.
• On Tuesday, June 3rd, William Lewis sold 5,472 shares of Insmed stock. The stock was sold at an average price of $71.50, for a total value of $391,248.00.
• On Monday, June 2nd, William Lewis sold 6,830 shares of Insmed stock. The shares were sold at an average price of $71.31, for a total value of $487,047.30.
• On Tuesday, May 20th, William Lewis sold 6,830 shares of Insmed stock. The stock was sold at an average price of $67.72, for a total transaction of $462,527.60.
• On Tuesday, May 20th, William Lewis sold 21,057 shares of Insmed stock. The stock was sold at an average price of $67.65, for a total transaction of $1,424,506.05.
• On Wednesday, May 14th, William Lewis sold 3,771 shares of Insmed stock. The shares were sold at an average price of $65.61, for a total value of $247,415.31.
• On Tuesday, May 13th, William Lewis sold 17,442 shares of Insmed stock. The shares were sold at an average price of $66.97, for a total transaction of $1,168,090.74.
• On Thursday, May 1st, William Lewis sold 6,830 shares of Insmed stock. The stock was sold at an average price of $72.57, for a total transaction of $495,653.10.

Insmed Stock Up 1.0%

NASDAQ:INSM traded up $0.98 during mid-day trading on Tuesday, reaching $102.87. The stock had a trading volume of 3,953,124 shares, compared to its average volume of 2,294,743. The stock has a market cap of $19.52 billion, a P/E ratio of -17.29 and a beta of 0.90. The business's 50 day moving average is $83.40 and its 200 day moving average is $77.44. The company has a debt-to-equity ratio of 11.38, a current ratio of 5.86 and a quick ratio of 5.44. Insmed, Inc. has a fifty-two week low of $60.40 and a fifty-two week high of $106.83.

Insmed (NASDAQ:INSM - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) EPS for the quarter, missing the consensus estimate of ($1.36) by ($0.06). Insmed had a negative return on equity of 446.98% and a negative net margin of 265.93%. The business had revenue of $92.82 million for the quarter, compared to analyst estimates of $91.63 million. During the same quarter last year, the company earned ($1.06) EPS. The business's revenue for the quarter was up 22.9% compared to the same quarter last year. As a group, sell-side analysts predict that Insmed, Inc. will post -4.56 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts have commented on INSM shares. Citigroup upgraded shares of Insmed to a "buy" rating in a research report on Tuesday, June 10th. Jefferies Financial Group reissued a "buy" rating on shares of Insmed in a report on Tuesday, June 10th. Wells Fargo & Company lifted their target price on Insmed from $107.00 to $119.00 and gave the company an "overweight" rating in a research note on Wednesday, June 11th. Leerink Partners lifted their price target on Insmed from $100.00 to $115.00 and gave the company an "outperform" rating in a research report on Tuesday, June 10th. Finally, Morgan Stanley upped their price objective on Insmed from $90.00 to $102.00 and gave the company an "overweight" rating in a report on Wednesday, June 11th. One equities research analyst has rated the stock with a sell rating and seventeen have issued a buy rating to the company's stock. According to data from MarketBeat, Insmed has an average rating of "Moderate Buy" and an average price target of $108.07.

Hedge Funds Weigh In On Insmed

Several institutional investors have recently bought and sold shares of the stock. Public Employees Retirement System of Ohio acquired a new position in Insmed in the 2nd quarter valued at $5,578,000. Assenagon Asset Management S.A. increased its stake in shares of Insmed by 84.5% in the second quarter. Assenagon Asset Management S.A. now owns 73,404 shares of the biopharmaceutical company's stock worth $7,387,000 after purchasing an additional 33,626 shares during the period. Fulton Bank N.A. lifted its position in shares of Insmed by 21.0% during the 2nd quarter. Fulton Bank N.A. now owns 5,416 shares of the biopharmaceutical company's stock worth $545,000 after purchasing an additional 940 shares during the last quarter. Wealth Enhancement Advisory Services LLC boosted its stake in Insmed by 17.9% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 4,446 shares of the biopharmaceutical company's stock valued at $435,000 after purchasing an additional 674 shares during the period. Finally, Longboard Asset Management LP acquired a new stake in Insmed in the 2nd quarter valued at approximately $205,000.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.